In its 2020 Drug Trend Report, Cigna Corp. division Evernorth said total drug costs rose 4% for its commercial plans, including both utilization and unit costs. The COVID-19 pandemic led to an across-the-board decline in the percentage of new medication users as well as improved adherence among people taking medications for chronic conditions. Among the top 15 therapy classes ranked by per-member per-year spend for the commercial plans, inflammatory conditions remained the top of the list, at $241.34 PMPY average spending, followed by diabetes at $145.24.
SOURCE: Evernorth. Visit https://www.evernorth.com/drug-trend-report.